Howard A "Skip" Burris, III, MD

Articles

Dr. Burris on the Utility of Sacituzumab Govitecan in Metastatic TNBC

August 21st 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses ​the utility of sacituzumab govitecan-hzi​y in metastatic triple-negative breast cancer.

Dr. Burris on Predictive Biomarkers for Chemoimmunotherapy in TNBC

August 7th 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses using biomarkers to determine the benefits of immunotherapy and chemotherapy in triple-negative breast cancer.

Dr. Howard Burris on Patient-Reported Outcomes of MARIANNE

July 9th 2016

Dr. Burris on the Impact of the ASCO Annual Meeting

May 28th 2015

Howard Burris, III, MD, chief medical officer and executive director of Drug Development at the Sarah Cannon Research Institute discusses the importance of the ASCO annual meeting, taking place May 29 - June 2.

Dr. Howard Burris Discusses the mTOR Inhibitor Everolimus

September 5th 2012

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the mTOR Inhibitor Everolimus for HER2-Negative Breast Cancer.

Dr. Burris on Using Recurrence Scores to Predict pCR

February 23rd 2012

Dr. Howard Burris from Sarah Cannon Research Institute Discusses Recurrence Scores Predicting pCR

Dr. Burris Discusses the Stratification of Clinical Trials

February 8th 2012

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the Stratification of Clinical Trials

Dr. Burris Discusses Targeting the mTOR Pathway

January 31st 2012

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses Targeting the mTOR Pathway